Related Experiment Video
Updated: Jun 12, 2026
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma
1The Moffitt Cancer Center, Programs of Molecular Oncology and Cutaneous Oncology, 12902 Magnolia Drive, Tampa, FL, 33612, USA. keiran.smalley@moffitt.org
Abstract:
PLX-4032 is a small-molecule, orally available B-Raf kinase inhibitor being developed by Plexxikon Inc and Hoffman-La Roche Ltd for the treatment of cancers harboring activating BRAF mutations. The primary focus of development is in melanoma (> 50% harbor activating BRAF mutations) with other solid tumors, such as colorectal carcinoma (> 10% harbor BRAF mutations), also under investigation. Purified kinase assays have demonstrated that PLX-4032 and its related analogs are highly potent inhibitors of B-Raf activity, with 3-fold selectivity for the V600E mutation over the wild-type kinase. In preclinical models, PLX-4032 and its analogs inhibited the growth of BRAFV600E-positive melanoma cell lines both in vitro and in vivo. In phase I clinical trials, PLX-4032 was well tolerated and objective responses were observed in several patients with BRAFV600E-positive tumors. Responses correlated well with inhibition of intratumoral phospho-ERK and cell proliferation, and reductions in fluorodeoxyglucose uptake on PET scanning. A preliminary analysis of this phase I data suggested that progression-free survival was approximately 7 months, and phase II and III clinical trials are now underway. These studies provide the proof-of-concept for B-Raf as a therapeutic target in melanoma.
Insights
PLX-4032, a B-Raf kinase inhibitor, shows promise in treating cancers with BRAF mutations, particularly melanoma. Clinical trials indicate it is well-tolerated and effective, with ongoing studies to confirm its therapeutic potential.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Activating BRAF mutations are key drivers in various cancers, notably melanoma.
- PLX-4032 targets B-Raf kinase, a critical enzyme in cancer cell signaling pathways.
- Targeting BRAF mutations represents a promising therapeutic strategy for BRAF-mutated cancers.
Purpose of the Study:
- To evaluate the safety and efficacy of PLX-4032, an orally available B-Raf kinase inhibitor.
- To assess the therapeutic potential of PLX-4032 in preclinical models and early-phase clinical trials for BRAF-mutated cancers.
- To establish proof-of-concept for B-Raf as a viable therapeutic target in melanoma treatment.
Main Methods:
- In vitro and in vivo studies using purified kinase assays and preclinical cancer models.
- Phase I clinical trials to assess tolerability, safety, and preliminary efficacy of PLX-4032.
- Biomarker analysis including intratumoral phospho-ERK, cell proliferation, and fluorodeoxyglucose uptake via PET scanning.
Main Results:
- PLX-4032 demonstrated high potency and selectivity for the BRAF V600E mutation.
- Preclinical studies showed inhibition of tumor growth in BRAFV600E-positive melanoma cell lines.
- Phase I trials reported good tolerability, objective responses in patients, and correlation with biomarker inhibition.
Conclusions:
- PLX-4032 is a potent B-Raf inhibitor with demonstrated efficacy in preclinical and early clinical settings.
- The drug shows promise for treating melanoma and other solid tumors harboring BRAF mutations.
- Further clinical trials (Phase II and III) are warranted to confirm the therapeutic benefit of PLX-4032.
